122,666 Shares in GeneDx Holdings Corp. $WGS Bought by Capital Research Global Investors

Capital Research Global Investors acquired a new position in shares of GeneDx Holdings Corp. (NASDAQ:WGS) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 122,666 shares of the company’s stock, valued at approximately $15,954,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Jones Financial Companies Lllp raised its holdings in shares of GeneDx by 664.3% during the third quarter. Jones Financial Companies Lllp now owns 214 shares of the company’s stock worth $25,000 after acquiring an additional 186 shares during the period. Ramirez Asset Management Inc. acquired a new stake in shares of GeneDx during the fourth quarter worth $33,000. Bank Julius Baer & Co. Ltd Zurich bought a new position in GeneDx in the fourth quarter valued at $35,000. Quarry LP grew its position in GeneDx by 248.8% in the third quarter. Quarry LP now owns 293 shares of the company’s stock valued at $32,000 after purchasing an additional 209 shares in the last quarter. Finally, Gordian Capital Singapore Pte Ltd bought a new position in GeneDx in the third quarter valued at $65,000. 61.72% of the stock is currently owned by institutional investors and hedge funds.

More GeneDx News

Here are the key news stories impacting GeneDx this week:

• Positive Sentiment: Director Casdin Capital, LLC bought 50,000 shares at an average price of $52.86, adding to a recent buying streak that may signal confidence from a major insider. SEC filing
• Positive Sentiment: Casdin Capital also disclosed a larger purchase of 150,000 shares at $56.44 on June 4, reinforcing the impression of insider accumulation after the stock’s recent weakness. SEC filing
• Neutral Sentiment: GeneDx also presented at Goldman Sachs’ Global Healthcare Conference, which may have helped keep the stock in focus, but no major new operating update was highlighted in the transcript. Conference transcript
• Neutral Sentiment: Analyst sentiment remains mixed-to-positive overall, with the stock carrying an average “Moderate Buy” rating, though that view has not changed the near-term legal headline risk. Analyst rating update
• Negative Sentiment: Several law firms issued fresh class-action notices and lead-plaintiff reminders tied to GeneDx’s stock drop after its Q1 results, keeping investor attention on potential securities-fraud claims and litigation uncertainty. Class action alert
• Negative Sentiment: The lawsuits center on alleged misleading disclosures and a steep post-earnings selloff, which may continue to weigh on sentiment despite insider buying. Litigation report

Insider Transactions at GeneDx

In other news, Director Casdin Capital, Llc acquired 185,000 shares of the firm’s stock in a transaction dated Tuesday, May 19th. The stock was bought at an average price of $42.60 per share, with a total value of $7,881,000.00. Following the transaction, the director directly owned 3,367,164 shares in the company, valued at approximately $143,441,186.40. The trade was a 5.81% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Keith A. Meister acquired 533,758 shares of the firm’s stock in a transaction dated Thursday, May 7th. The stock was purchased at an average cost of $37.86 per share, with a total value of $20,208,077.88. Following the transaction, the director owned 3,761,908 shares in the company, valued at approximately $142,425,836.88. This trade represents a 16.53% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders bought 2,256,420 shares of company stock valued at $93,144,340 and sold 72,382 shares valued at $4,889,473. Company insiders own 29.60% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently weighed in on WGS. Piper Sandler reaffirmed an “overweight” rating and issued a $130.00 target price (down from $160.00) on shares of GeneDx in a research report on Tuesday, February 24th. BTIG Research decreased their target price on shares of GeneDx from $170.00 to $90.00 and set a “buy” rating for the company in a research report on Tuesday, May 5th. Weiss Ratings downgraded shares of GeneDx from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, June 1st. Wells Fargo & Company reaffirmed an “overweight” rating and issued a $75.00 target price (down from $155.00) on shares of GeneDx in a research report on Tuesday, May 5th. Finally, Craig Hallum reaffirmed a “buy” rating and issued a $85.00 target price on shares of GeneDx in a research report on Tuesday, May 5th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, GeneDx presently has an average rating of “Moderate Buy” and an average target price of $96.43.

GeneDx Stock Up 8.7%

GeneDx stock opened at $56.33 on Wednesday. The company has a market cap of $1.67 billion, a P/E ratio of -21.02 and a beta of 1.96. GeneDx Holdings Corp. has a 1-year low of $32.21 and a 1-year high of $170.87. The company has a fifty day simple moving average of $55.24 and a 200 day simple moving average of $91.57. The company has a current ratio of 3.09, a quick ratio of 2.95 and a debt-to-equity ratio of 0.38.

GeneDx (NASDAQ:WGS) last announced its quarterly earnings data on Monday, May 4th. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.22). GeneDx had a negative net margin of 17.58% and a positive return on equity of 9.15%. The firm had revenue of $102.25 million during the quarter, compared to the consensus estimate of $112.46 million. During the same period last year, the business earned ($0.23) EPS. Research analysts anticipate that GeneDx Holdings Corp. will post -1 earnings per share for the current fiscal year.

About GeneDx

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.